Our Full-Service Clinical Research Units
Quebec City, Canada

Celebrating more than 30 years of excellence in early phase research
First established in 1994, today this is a 25,000 sq. ft. state-of-the-art facility, with up to 202 beds in five independent units as well as a full-service Bioanalysis laboratory, staffed by approximately 160 on-site nurses, pharmacists, clinical research associates and biometricians. The facility is equipped to conduct complex, high-intensity clinical studies with participant comfort and safety top of mind.
Key features include:
- Wide range of healthy participant and patient enrollment capabilities that seek to meet the specific needs of your study
- On-site pharmacy (temperature and humidity-controlled) equipped to perform nonsterile compounding and aseptic preparations (clean room)
- Extensive participant data base and access to special populations
- Two screening centers: Quebec City, with a satellite center in Montreal
- Five km from hospitals with emergency facilities
- Recognized and frequently inspected by worldwide regulatory agencies, with a strong reputation for safety and compliance, with no 483s on last five FDA inspections
- On-site deployment of the ClinSpark® eSource platform, offering e-data capture and management specifically designed for Phase I clinical trials
Would you like more information?

An unwavering commitment to safe and ethical early phase research
Our first concern is participant welfare as we strive – in partnership with our customers – to advance the delivery of life-changing therapies.
In addition to being subject to multiple layers of external oversight, Syneos Health has its own robust internal controls and processes to address participant safety and well-being, including:
- A thorough informed consent process that clearly describes study requirements, risks and the need for participant transparency
- Rigorous medical screening to determine study eligibility
- Around-the-clock monitoring to promptly address potential adverse events
These activities are subject to Sponsor audit or Health Authority inspection.